(RTTNews) - Alumis Inc. (ALMS), a clinical-stage biopharmaceutical company, on Wednesday announced positive topline results from its Phase 1 clinical trial of A-005, a CNS-penetrant TYK2 inhibitor.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback